基本信息
浏览量:0
职业迁徙
个人简介
Dr. Yvonne Chen is an Associate Professor of Microbiology, Immunology, and Molecular Genetics at the University of California, Los Angeles. Prior to joining UCLA in 2013, Dr. Chen was a Junior Fellow in the Harvard Society of Fellows. She received her B.S. in Chemical Engineering from Stanford University and her Ph.D. in Chemical Engineering from the California Institute of Technology. She performed postdoctoral research at the Seattle Children’s Research Institute and the Department of Systems Biology at Harvard Medical School. The Chen lab’s work on engineering next-generation T-cell therapies for cancer has been recognized by the NIH Director’s Early Independence Award, the NSF CAREER Award, the Hellman Fellowship, the ACGT Young Investigator Award in Cell and Gene Therapy for Cancer, the Mark Foundation Emerging Leader Award, and the Cancer Research Institute Lloyd J. Old STAR Award. Dr. Chen is also a Member Researcher in the Parker Institute for Cancer Immunotherapy.
Research Interests
The Chen Laboratory is focused on applying synthetic biology and biomolecular engineering techniques to develop robust cell-based therapies for otherwise intractable diseases. We are particularly interested in engineering multi-functional T cells that can accurately identify and effectively eliminate tumor cells, in part by overcoming the various defense mechanisms associated with cancers and their microenvironments. Bispecific chimeric antigen receptor (CAR)-T cells developed in our laboratory is being tested in the clinic, and current projects include the development of next-generation CAR-T cells with enhanced specificity, reduced toxicity, and the ability to overcome tumor-associated immunosuppression.
Research Interests
The Chen Laboratory is focused on applying synthetic biology and biomolecular engineering techniques to develop robust cell-based therapies for otherwise intractable diseases. We are particularly interested in engineering multi-functional T cells that can accurately identify and effectively eliminate tumor cells, in part by overcoming the various defense mechanisms associated with cancers and their microenvironments. Bispecific chimeric antigen receptor (CAR)-T cells developed in our laboratory is being tested in the clinic, and current projects include the development of next-generation CAR-T cells with enhanced specificity, reduced toxicity, and the ability to overcome tumor-associated immunosuppression.
研究兴趣
论文共 108 篇作者统计合作学者相似作者
按年份排序按引用量排序主题筛选期刊级别筛选合作者筛选合作机构筛选
时间
引用量
主题
期刊级别
合作者
合作机构
JOURNAL OF EXPERIMENTAL MEDICINEno. 2 (2024)
Meng-Yin Lin, Eunwoo Nam, Ryan M Shih, Amanda Shafer, Amber Bouren, Melanie Ayala Ceja,Caitlin Harris,Mobina Khericha, Kenny H Vo, Minsoo Kim, Chi-Hong Tseng,Yvonne Y Chen
The Journal of experimental medicineno. 6 (2024)
Sameeha Jilani,Justin D. Saco, Edurne Mugarza, Aleida Pujol-Morcillo, Jeffrey Chokry,Clement Ng,Gabriel Abril-Rodriguez, David Berger-Manerio, Ami Pant, Jane Hu, Rubi Gupta,Agustin Vega-Crespo,
Nature Communicationsno. 1 (2024): 1-19
Wei Ma, Nuan Wang,Hye Yeon Choi, Lin Ziying, Nicolette Fajardo, Royce Ilaga, Risa Machida, Zhou Lin, Ambika Ramrakhiani,Yvonne Y. Chen,Linda Sher,Stanley M. Tahara,
Cancer Researchno. 7_Supplement (2024)
Gene therapyno. 10-11 (2023): 753-755
crossref(2023)
Cancer Researchno. 8_Supplement (2023): CT023-CT023
引用0浏览0引用
0
0
CURRENT OPINION IN BIOTECHNOLOGY (2023): 103020-103020
bioRxiv : the preprint server for biology (2023)
加载更多
作者统计
合作学者
合作机构
D-Core
- 合作者
- 学生
- 导师
数据免责声明
页面数据均来自互联网公开来源、合作出版商和通过AI技术自动分析结果,我们不对页面数据的有效性、准确性、正确性、可靠性、完整性和及时性做出任何承诺和保证。若有疑问,可以通过电子邮件方式联系我们:report@aminer.cn